—各奖项申报陆续启动,欢迎关注—4月29日,Creyon Bio宣布与礼来达成一项全球性许可及多靶点研究合作,共同聚焦创新靶向RNA的寡核苷酸疗法在多种疾病中的发现、开发与商业化。Creyon将利用其独特的AI驱动寡核苷酸工程化引擎,为礼来指定的靶点设计并优化候选化合物。根据协议条款,Creyon将获得1300万美元预付款,并在达成特定里程碑后,有资格获得超10亿美元的研发及商业化付款。礼来获得...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.